# Alkermes Announces Positive Topline Results From REVITALYZ℠ Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia
Canonical URL: https://biopharmsignal.com/news/ALKS/alkermes-announces-positive-topline-results-from-revitalyz-phase-3-study-evaluating-lumryzr-sodium-oxybate-extended-release-in-adults-with-idiopathic-hypersomnia
Ticker: ALKS
Company: Alkermes plc
Source: Alkermes plc
Published: 2026-05-12 11:00 EST
Original Source URL: https://investor.alkermes.com
## Summary

– LUMRYZ Met All Primary and Key Secondary Endpoints Demonstrating Statistically Significant and Clinically Meaningful Improvements Compared to Placebo in Excessive Daytime Sleepiness and Patient-Reported Disease Severity – – Safety Profile Consistent With Known Safety Profile of LUMRYZ – DUBLIN

## Article Body
– LUMRYZ Met All Primary and Key Secondary Endpoints Demonstrating Statistically Significant and Clinically Meaningful Improvements Compared to Placebo in Excessive Daytime Sleepiness and Patient-Reported Disease Severity – – Safety Profile Consistent With Known Safety Profile of LUMRYZ – DUBLIN
## Recent Company News
- 2026-06-04 11:00 EST — [Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research](https://biopharmsignal.com/news/ALKS/alkermes-to-present-new-data-on-alixorexton-and-lumryzr-sodium-oxybate-at-sleep-2026-highlighting-breadth-of-sleep-medicine-research) — Source: Alkermes plc
- 2026-06-03 20:05 EST — [Alkermes to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference](https://biopharmsignal.com/news/ALKS/alkermes-to-participate-in-the-goldman-sachs-47th-annual-global-healthcare-conference) — Source: Alkermes plc
- 2026-05-26 11:00 EST — [Alkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Annual Meeting](https://biopharmsignal.com/news/ALKS/alkermes-to-showcase-leadership-in-psychiatry-and-orexin-biology-with-new-data-at-the-american-society-of-clinical-psychopharmacology-annual-meeting) — Source: Alkermes plc
- 2026-05-21 11:00 EST — [Alkermes Showcases Data From Psychiatry Portfolio and Sleep Research into Real World Patient Experience at Spring 2026 Scientific Conferences](https://biopharmsignal.com/news/ALKS/alkermes-showcases-data-from-psychiatry-portfolio-and-sleep-research-into-real-world-patient-experience-at-spring-2026-scientific-conferences) — Source: Alkermes plc
- 2026-05-12 11:00 EST — [Alkermes Announces Positive Topline Results From REVITALYZ℠ Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia](https://biopharmsignal.com/news/ALKS/alkermes-announces-positive-topline-results-from-revitalyz-phase-3-study-evaluating-lumryzr-sodium-oxybate-extended-release-in-adults-with-idiopathic-hypersomnia) — Source: Alkermes plc
## Related News
- 2026-07-22 20:15 EST — BFRG — [BullFrog AI to Participate in the BTIG Virtual Biotechnology Conference](https://biopharmsignal.com/news/BFRG/bullfrog-ai-to-participate-in-the-btig-virtual-biotechnology-conference-5880a10e)
- 2026-07-22 20:05 EST — AZTA — [Azenta Announces Fiscal 2026 Third Quarter Conference Call and Webcast](https://biopharmsignal.com/news/AZTA/azenta-announces-fiscal-2026-third-quarter-conference-call-and-webcast-48419fff)
- 2026-07-22 20:05 EST — VKTX — [Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026](https://biopharmsignal.com/news/VKTX/viking-therapeutics-to-report-financial-results-for-second-quarter-2026-on-july--bbf2553f)
- 2026-07-22 20:01 EST — AXON — [Axon to Release Second Quarter 2026 Earnings on August 5, 2026](https://biopharmsignal.com/news/AXON/axon-to-release-second-quarter-2026-earnings-on-august-5-2026-66120902)
- 2026-07-22 12:39 EST — ARTL — [New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy — Reinforcing the Case for Artelo's Optimized ART12.11 CBD Composition](https://biopharmsignal.com/news/ARTL/new-analysis-of-over-50-studies-showed-that-all-the-non-prescription-cbd-product-a3445432)